Welcome to Equity.Guru’s Roundtable where our writers weigh in on the pros and cons of a spotlight company, break out where they see value, and help you avoid public…
NM.C
Novamind (NM.CN) is a company that addresses mental health. Utilizing a network of psychiatry clinics, research sites and therapeutic retreats specialized in psychedelic medicine. The company states they are…
Why some stocks are undervalued A lot of things go into determining a company’s share price, but in a young emerging industry like psychedelics, many of the traditional measurements…
‘Growth hacking’ Early on in the shroom boom critics had one major pain point – legalization is too far away. I remember the stiffs at the Cannacord conference a…
Novamind (NM.C) announced that they have opened a new Novamind Client Care Center to manage the “overwhelming demand for its treatments”. The new client care center is located in…
Novamind (NM.C) announced they are opening four new Cedar Psychiatric clinics, doubling the number of clinics in there network. The expanded capacity for the new clinics is intended to…
Novamind (NM.C) shared the preliminary findings from two studies which involved using Ketamine-Assisted Psychotherapy (KAP) to treat eating disorders. The studies were done in collaboration with Center for Change….
Cedar Clinical Research Novamind (NM.C) announced today it’s increasing its investment in the Australian-based drug company Bionomics (BNO.ASX). The company is focused primarily on anxiety, PTSD, and central nervous…
Cluster B Several psychedelics companies are out to target depression, anxiety, PTSD, and substance use disorder – but surprisingly we don’t hear much about personality disorders. Despite an…
Novamind (NM.C) announced that their wholly-owned subsidiary, Cedar Clinical Research (CCR), has been selected by Merck to be a key research site for a clinical trial focused on treatment-resistant…